John D. Schuetz, PhD, is the inaugural Editor-in-Chief of ASPET Discovery, the newest Gold Open Access journal of the American Society for Pharmacology and Experimental Therapeutics. In partnership with Elsevier Publishing Company, ASPET Discovery, a peer-reviewed Open Access journal, will publish bi-monthly and include a range of article types including original research articles and minireviews that address all areas of pharmacology and experimental therapeutics. Dr. Schuetz will serve a three-year term that can be renewed for one additional three-year term.
Listen to ASPET President, Dr. Carol Beck, give updates on ASPET 2025 registration, ASPET Discovery, the Journal Editorial Fellows and more!
The start of 2025 marks an important milestone for ASPET and its highly respected and influential journals program. Beginning January 1, all of ASPET’s wholly owned journals (The Journal of Pharmacology and Experimental Therapeutics, Pharmacological Reviews, Drug Metabolism and Disposition, and Molecular Pharmacology) are now published on Elsevier’s platform. This change comes for ASPET after approximately 30 years of self-publishing, so rest assured that this change was not made lightly.
A Conversation with ASPET’s Partnerships Committee Co-Chair, Micheline Piquette-Miller, PhD
The first cohort of the American Society for Pharmacology and Experimental Therapeutics’ (ASPET) Inclusion, Diversity, Equity and Accessibility (IDEA) faculty scholars have been selected. The ASPET IDEA Committee, under the direction of IDEA Committee Chair Ashim Malhotra, PhD, chose 13 ASPET members to participate based on an application process that included a Curriculum Vitae, a statement of interest and a summary of participation goals. The program started in the fall.
Each month, ASPET welcomes new members to our home for pharmacology. This month, we recognize 144 individuals from 97 universities, colleges and companies who have joined 4,000 other members in the pharmacology community.
Honoring ASPET members who have passed.
Now in its second year, ASPET’s science policy newsletter, Advocacy Brief, helps members keep up with breaking news on policy decisions and legislation affecting biomedical research, research funding opportunities, regulations and other important matters impacting pharmacology and pharmacologists.
A showcase of early-career scientists—what drives them and why pharmacology is important to them.
